Mersana Therapeutics, Inc.
MRSN
$7.68
$0.0250.33%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 29.34% | 45.10% | 59.69% | 62.13% | 51.31% |
| Total Depreciation and Amortization | -17.35% | -6.17% | 7.32% | 23.89% | 49.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -13.18% | -18.42% | -20.33% | -25.07% | -29.79% |
| Change in Net Operating Assets | 53.04% | 62.58% | -63.82% | -159.23% | -145.17% |
| Cash from Operations | 39.83% | 54.21% | 51.24% | 49.48% | -51.54% |
| Capital Expenditure | 100.00% | 100.00% | 93.91% | 79.82% | 60.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 82.21% | 134.49% | -90.52% | -131.47% | 191.24% |
| Cash from Investing | 86.08% | 141.58% | -90.46% | -133.91% | 186.25% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3,353.50% | -1,923.66% | -751.15% | 22.99% | 6.90% |
| Issuance of Common Stock | -95.89% | -99.46% | -93.36% | -95.42% | -95.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | 100.00% |
| Cash from Financing | -237.23% | -106.17% | -95.68% | -95.55% | -95.96% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 125.78% | 156.89% | -246.27% | -4,980.28% | -955.62% |